BSP:LILY34 (USA)  
Eli Lilly and Co logo

Eli Lilly and Co

R$ 816.91 (+2.58%) Sep 23
On watch
P/E:
50.40
P/B:
34.63
Market Cap:
R$ 1.55T ($ 294.87B)
Enterprise V:
R$ 1.59T ($ 301.43B)
Volume:
22.00
Avg Vol (2M):
1.11K
Also Trade In:
Volume:
22.00
Market Cap R$:
1.55T
Market Cap $:
294.87B
PE Ratio:
50.40
Avg Vol (2-Month):
1.11K
Enterprise Value R$:
1.59T
Enterprise Value $:
301.43B
PB Ratio:
34.63
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Financials (Next Earnings Date:2022-10-26 Est.)

BSP:LILY34's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 152,607.407
EPS (TTM) (R$) 16.213
Beta -0.17
Volatility % 30.59
14-Day RSI 54.27
14-Day ATR (R$) 18.212751
20-Day SMA (R$) 795.7555
12-1 Month Momentum % 30.13
52-Week Range (R$) 594.6 - 901.44
Shares Outstanding (Mil) 1,900.35

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Eli Lilly and Co Filings

Document Form Filing Date
No Filing Data

Eli Lilly and Co Analysis

Share your research